Key takeaway
This narrative review says incretin-based obesity medications cause weight loss comparable to bariatric surgery, but also rapid loss of muscle and bone and nutrient deficiencies, and suggests protein- and fiber-rich diets and supervised exercise to protect lean mass. It does not report numbers or pooled data, so how much these measures help is not quantified.
Study design
Research article
Reading basis
Published abstract
Reading focus
Design & applicability
The research question
Incretin-based medications have changed obesity treatment by producing large weight loss, but fast loss of body mass raises concern for muscle, bone and nutrition. The authors reviewed what nutritional, physical activity and adjunctive strategies are used in adults treated with these drugs to preserve lean mass and long-term health.
Who and how
Narrative literature review up to 31 October 2025 of studies on nutritional, physical activity and adjunctive interventions in adults with obesity treated with incretin-based medications. The abstract does not report the databases searched, the number of studies, a quality appraisal or any pooled estimates.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Incretin-based agents produce substantial weight loss, comparable to bariatric surgery, mostly from fat tissue.
- 2They also cause rapid reductions in muscle and bone mass, often with nutrient deficiencies, which may compromise metabolic health and physical function.
- 3Tailored nutrition is proposed to preserve lean mass and support lasting weight maintenance: reduced-calorie diets rich in protein and fiber, plus amino acid, vitamin and mineral supplements.
- 4Structured, supervised physical activity, including aerobic, resistance and strength training, is described as limiting muscle loss and improving functional capacity.
- 5Newer drugs that reduce fat while preserving lean mass, and approaches targeting the gut microbiota, are described as promising add-ons.
Limits & uncertainty
- 1The abstract gives no numbers on how much muscle or bone is lost, or how much diet and exercise prevent, so the size of the problem and of the benefit is unclear.
- 2A narrative review uses no fixed method for choosing studies, so evidence may be selected to fit the argument, and the quality of the evidence is not stated.
- 3Several recommendations, such as supplements, new drugs and microbiota approaches, are described as emerging rather than proven.
- 4This reading is based on the abstract only.
What to take from it
If someone is on one of these medications, protein intake and regular resistance exercise are sensible things to raise with their care team, since muscle loss is a recognised concern. The review does not provide target amounts or show that these measures prevent harm. Medication, supplements and diet changes should be decided with a clinician or dietitian.
Reading your own data
Body weight alone cannot show whether you are losing fat or muscle, so also log strength in a few lifts, grip strength, protein intake and training sessions. Track on the same scale and device and review monthly trends, and share the data with your care team.
How to read this evidence
The index does not establish a precise design. Read the methods before making causal claims; check population, comparator, outcomes and uncertainty in the source.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Background/objectives
Incretin-based medications have transformed obesity management by enabling substantial body weight reduction. However, the rapid and pronounced loss of body mass necessitates a comprehensive, multidisciplinary approach incorporating nutritional and physical activity strategies to preserve lean mass, optimize functional outcomes, and prevent long-term complications. This narrative review provides a critical overview of this emerging clinical concern, which is expected to gain increasing relevance in the coming years.
Methods
A literature review was conducted up to 31 October 2025, focusing on studies addressing nutritional, physical activity, and adjunctive interventions in adults with obesity treated with incretin-based medications.
Results
Incretin-based agents induce significant weight loss, comparable to bariatric surgery, predominantly targeting adipose tissue. Nevertheless, these medications also cause rapid reductions in muscle and bone mass, often accompanied by nutrient deficiencies, which may compromise metabolic health and physical function. Tailored nutritional strategies-including hypocaloric diets enriched in protein and fiber, as well as amino acid, vitamin, and mineral supplementation-are critical to preserve lean mass and support sustained weight maintenance. Concurrently, structured, supervised physical activity, encompassing aerobics, resistance, and strength training, mitigates muscle loss and enhances functional capacity. Emerging pharmacological agents designed to promote adipose tissue reduction while preserving lean mass, as well as interventions targeting gut microbiota modulation, may represent promising adjunctive strategies to optimize long-term outcomes further.
Conclusions
While incretin-based medications produce substantial weight loss, their impact on lean mass underscores the necessity of integrating personalized nutrition, supplementation, and structured exercise to preserve muscle, prevent malnutrition, and optimize long-term health and obesity outcomes.
Sources & attribution
Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review.
Barana L, De Fano M, Cavallo M, Manco M, Prete D, Fanelli CG, Porcellati F, Pippi R.
Nutrients · 2025-12-31
DOI: 10.3390/nu18010131 ↗PubMed · 41515247 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
Early time-restricted eating linked to more weight loss and lower insulin than late eating
Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.
BMJ Medicine
An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss
Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.
The New England Journal of Medicine
In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain
In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.
Cell Metabolism
Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)
Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.
The New England Journal of Medicine

